Allinaire Therapeutics
PrivateLast Round
Seed Round
Jan 30, 2026
Total Funding Raised
$2.83M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Allinaire Therapeutics operates in Healthcare & Life Sciences and is based in Cleveland, Ohio. Its latest recorded funding round was a Strategic round in May 2022.
Allinaire Therapeutics is a biotechnology company developing novel therapeutics for cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allinaire Therapeutics Comparables
Compare Allinaire Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ATXA Therapeutics | 79% | |
| Zymedi | 78% | |
| GSK plc | 77% |
For institutional investors. Book with your work email.
Allinaire Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jan 30, 2026 | ||||
| Strategic | May 2, 2022 | ||||
| Grant | Sep 19, 2017 | ||||
| Seed | Jan 26, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Allinaire Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMotiv | Seed |
| United States Department of Defense | Grant |
| BioCrossroads | Seed |
| IU Ventures | Seed |
| National Heart, Lung, and Blood Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 963% MoM, reaching 1.4K.
- Apr 17, 2026
Monthly visitors increased 77% MoM.
For institutional investors. Book with your work email.
Allinaire Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Allinaire Therapeutics's valuation, stock price, and market status.
Is Allinaire Therapeutics a public or private company?
Allinaire Therapeutics is a private company.
What is the current stock price of Allinaire Therapeutics?
Allinaire Therapeutics is a private company, so its shares have no public market price. Caplight tracks Allinaire Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allinaire Therapeutics worth (valuation)?
Valuation information for Allinaire Therapeutics is not publicly available.
Can I buy Allinaire Therapeutics stock?
Allinaire Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allinaire Therapeutics's last funding round?
Allinaire Therapeutics's most recent funding round was Seed Round on January 30, 2026.
Who are the main investors in Allinaire Therapeutics?
Key investors in Allinaire Therapeutics include BioMotiv, United States Department of Defense, BioCrossroads, IU Ventures, National Heart, Lung, and Blood Institute.
Will Allinaire Therapeutics IPO soon?
No public IPO plans have been announced for Allinaire Therapeutics.
How can I track Allinaire Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allinaire Therapeutics's shares on secondary markets.